Morphotek, Inc. Announces Initiation Of A New MORAb-004 Phase I Study In
Pediatric Patients With Relapsed/Refractory Solid Tumors
EXTON, Pa., Oct. 9, 2013
EXTON, Pa., Oct. 9, 2013 /PRNewswire/ --Morphotek®, Inc., a subsidiary of
Eisai Inc., announced today that the Children's Oncology Group (COG) has
opened enrollment in a Phase 1 clinical study with MORAb-004 in pediatric
patients with relapsed/refractory solid tumors. The open-label Phase 1 study
will assess the safety, tolerability and pharmacokinetics of MORAb-004
administered in weekly intravenous infusions in pediatric patients.
MORAb-004 is an investigational monoclonal antibody that specifically binds to
endosialin/tumor endothelial marker-1 (TEM-1). The target is found to be
expressed on the cell surface of cells called pericytes that are part of the
tumor blood vessel architecture, as well as on fibroblast cells that are part
of the tumor stroma. Morphotek obtained exclusive worldwide rights to develop
and commercialize this antibody from the Ludwig Institute for Cancer Research
"We are excited to have initiated this Phase 1 study of MORAb-004," stated
John Heyburn, Director of Clinical Operations at Morphotek. "New agents are
needed for cancer treatment and our strategy of using collaborations with
leading research groups provides us unique development opportunities."
"MORAb-004 is an antibody to target TEM-1/endosialin. Its mechanism of action
may eventually offer a new approach in our efforts to develop cancer
treatments," said Robin Norris, M.D., COG Study Chair for the trial. "We are
very pleased to have the opportunity to collaborate with Morphotek in the
evaluation of this agent."
Further information on the clinical study can be found at
www.clinicaltrials.gov, study number NCT 01748721.
Morphotek^®, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company
specializing in the development of protein and antibody products through the
use of a novel and proprietary gene evolution technology. The technology has
been successfully applied to a broad variety of cell lines and organisms to
yield genetically diverse offspring that are suitable for pharmaceutical
product development in the areas of antibody therapeutics, protein
therapeutics, product manufacturing, drug target discovery, and improved
output traits for commercial applications. The company is currently focusing
its platform on the development and manufacturing of therapeutic antibodies
for the treatment of cancer, inflammation and infectious disease. For more
information, please visit www.morphotek.com.
About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to
patients and their families, and helping to increase the benefits health care
provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co.,
Ltd., our passionate commitment to patient care is the driving force behind
our efforts to help address unmet medical needs. We are a fully integrated
pharmaceutical business with discovery, clinical, manufacturing and marketing
capabilities. Our key areas of commercial focus include oncology and specialty
care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more
about Eisai Inc., please visit us at www.eisai.com/US.
Eisai Inc. has affiliates that are part of a global product creation
organization that includes R&D facilities in Massachusetts, New Jersey, North
Carolina and Pennsylvania, as well as a global demand chain organization that
includes manufacturing facilities in Maryland and North Carolina. Eisai's
global areas of R&D focus include neuroscience; oncology; metabolic disorders;
vascular, inflammatory and immunological reaction; and antibody-based
About Children's Oncology Group (COG)
The Children's Oncology Group (www.childrensoncologygroup.org) is the world's
largest organization devoted exclusively to childhood and adolescent cancer
research. The Children's Oncology Group (COG) unites more than 8,000 experts
in childhood cancer at more than 200 leading children's hospitals,
universities, and cancer centers across North America, Australia, New Zealand,
and parts of Europe in the fight against childhood cancer. Today, more than
90% of the 13,500 children and adolescents diagnosed with cancer each year in
the United States are cared for at COG member institutions. Research
performed by the Children's Oncology Group institutions over the past fifty
years has transformed childhood cancer from a virtually incurable disease to
one with a combined 5-year survival rate of 80%. COG's mission is to improve
the cure rate and outcome for all children with cancer.
Contacts: Media and Investor Media Inquiries Investor Inquiries
Rod Dausch Laurie Landau Alex Scott
Morphotek, Inc. Eisai Inc. Eisai Inc.
610-423-6111 201-746-2510 201-746-2177
Dausch@morphotek.com firstname.lastname@example.org email@example.com
SOURCE Morphotek, Inc.
Press spacebar to pause and continue. Press esc to stop.